RT @Stiddyo: #POS0930 @XBaraliakos investigated baseline predictors differential treatment effect on ASAS20 response at
Tweet Content
#POS0930
@XBaraliakos investigated baseline predictors differential treatment effect on ASAS20 response at week 12 of 473 ax-PsA using MAXIMISE trial data (#Secukinumab)
-> Only nail dystrophy
OR: 3 (150mg)
OR: 5 (300mg)
🤔But why?
#EULAR2021 @RheumNow https://t.co/srb6jGgBqe
Show on Archive Page
On
Display in Search Results
On
PDQ
Off